AIM Vaccine Co., Ltd. (HKG:6660)

Market Cap	1.82B -62.1%
Revenue (ttm)	1.16B -20.7%
Net Income	-770.22M
EPS	-0.63
Shares Out	1.23B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,200
Open	1.535
Previous Close	1.535
Day's Range	1.415 - 1.535
52-Week Range	1.200 - 3.960
Beta	0.10
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 23, 2026

About AIM Vaccine

AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China and internationally. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 1,353
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6660

Financial Performance

In 2025, AIM Vaccine's revenue was 1.17 billion, a decrease of -9.29% compared to the previous year's 1.29 billion. Losses were -675.46 million, 143.6% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error